(epirubicin + cisplatin + (5-fluorouracil or capecitabine)) or (5-fluorouracil + leucovorin + oxaliplatin + docetaxel)

This entry refers to the perioperative chemotherapy regimens utilized in the POWERRANGER clinical trial (NCT03324191), led by Dr. Gordon Buduhan. The treatment involves a choice between two standard-of-care regimens for resectable esophageal or gastroesophageal junction (GEJ) adenocarcinoma: FLOT (5-fluorouracil, leucovorin, oxaliplatin, and docetaxel) or ECF/ECX (epirubicin, cisplatin, and either 5-fluorouracil or capecitabine). These regimens function through multiple mechanisms, including DNA alkylation, inhibition of thymidylate synthase, topoisomerase II inhibition, and microtubule stabilization, to induce tumor cell death. The trial compares these perioperative chemotherapy options against neoadjuvant chemoradiation (carboplatin/paclitaxel plus radiation) to determine the most effective preoperative strategy for improving survival in patients with localized adenocarcinoma of the esophagus or GE junction.

Other names

FLOTECFECXperioperative chemotherapy